Merck strengthens immunotherapy expertise with $773m buy

11-06-2019

Merck strengthens immunotherapy expertise with $773m buy

Katherine Welles / Shutterstock.com

US-based Merck & Co has announced plans to buy Tilos Therapeutics, its latest acquisition in the immunotherapy space.


Merck & Co, Tilos Therapeutics, M&A, mergers and acquisitions, immunotherapy, oncology, Boehringer Ingelheim, Harvard Medical School

LSIPR